糖尿病管理デバイスの世界市場2021年-2025年

◆英語タイトル:Global Diabetes Management Devices Market 2021-2025
◆商品コード:IRTNTR70599
◆発行会社(リサーチ会社):Technavio
◆発行日:2021年5月24日
◆ページ数:約120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:北米、ヨーロッパ、アジア、その他
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

テクナビオ社は、糖尿病管理デバイスの世界市場規模が2021年から2025年まで年平均8%以上成長し、143.1億ドルに達すると予測しています。本調査資料では世界の糖尿病管理デバイス市場について調査・分析し、エグゼクティブサマリー、市場状況、市場規模、ファイブフォース分析、製品別(血糖値モニタリング装置、インスリン送達システム)分析、エンドユーザー別分析、顧客状況、地域別状況、企業状況、企業分析など、以下の項目を掲載しています。
・エグゼクティブサマリー
・市場状況
・市場規模
・ファイブフォース分析
・糖尿病管理デバイスの世界市場規模:製品別(血糖値モニタリング装置、インスリン送達システム)
・糖尿病管理デバイスの世界市場規模:エンドユーザー別
・顧客状況
・地域別状況
・企業状況
・企業分析
【レポートの概要】

Global Diabetes Management Devices Market 2021-2025

Technavio has been monitoring the diabetes management devices market and it is poised to grow by USD 14.31 billion during 2021-2025, progressing at a CAGR of over 8% during the forecast period. Our report on the diabetes management devices market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the rising global burden of diabetes and favorable government initiatives. In addition, the rising global burden of diabetes is anticipated to boost the growth of the market as well.

The diabetes management devices market analysis includes the product segmentation and geographic landscape.
Technavio’s diabetes management devices market is segmented as below:

By Product
• Blood glucose monitoring devices
• Insulin delivery systems

By Geography
• North America
• Europe
• Asia
• ROW

This study identifies the growing demand for advanced insulin delivery devices as one of the prime reasons driving the diabetes management devices market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on diabetes management devices market covers the following areas:
• Diabetes management devices market sizing
• Diabetes management devices market forecast
• Diabetes management devices market industry analysis

Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading diabetes management devices market vendors that include Abbott Laboratories, B. Braun Melsungen AG, Bionime Corp., Dexcom Inc., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., LifeScan IP Holdings LLC, Medtronic Plc, Novo Nordisk AS, and PHC Holdings Corp. Also, the diabetes management devices market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit – https://www.technavio.com/report/diabetes-management-devices-market-industry-analysis

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

【レポートの目次】

• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2020
o Market outlook: Forecast for 2020 – 2025
• Five Forces Analysis
o Five forces summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Product
o Market segments
o Comparison by Product
o Blood glucose monitoring devices – Market size and forecast 2020-2025
o Insulin delivery systems – Market size and forecast 2020-2025
o Market opportunity by Product
• Market Segmentation by End-user
o Market segments
• Customer landscape
o Customer landscape
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America – Market size and forecast 2020-2025
o Europe – Market size and forecast 2020-2025
o Asia – Market size and forecast 2020-2025
o ROW – Market size and forecast 2020-2025
o Key leading countries
o Market opportunity by geography
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Overview
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o Abbott Laboratories
o B. Braun Melsungen AG
o Bionime Corp.
o Dexcom Inc.
o Eli Lilly and Co.
o F. Hoffmann-La Roche Ltd.
o LifeScan IP Holdings LLC
o Medtronic Plc
o Novo Nordisk AS
o PHC Holdings Corp.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations

Exhibits
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Parent market
• 9: Market characteristics
• 10: Offerings of vendors included in the market definition
• 11: Market segments
• 12: Global – Market size and forecast 2020 – 2025 ($ billion)
• 13: Global market: Year-over-year growth 2020 – 2025 (%)
• 14: Five forces analysis 2020 & 2025
• 15: Bargaining power of buyers
• 16: Bargaining power of suppliers
• 17: Threat of new entrants
• 18: Threat of substitutes
• 19: Threat of rivalry
• 20: Market condition – Five forces 2020
• 21: Product – Market share 2020-2025 (%)
• 22: Comparison by Product
• 23: Blood glucose monitoring devices – Market size and forecast 2020-2025 ($ billion)
• 24: Blood glucose monitoring devices – Year-over-year growth 2020-2025 (%)
• 25: Insulin delivery systems – Market size and forecast 2020-2025 ($ billion)
• 26: Insulin delivery systems – Year-over-year growth 2020-2025 (%)
• 27: Market opportunity by Product
• 28: Customer landscape
• 29: Market share by geography 2020-2025 (%)
• 30: Geographic comparison
• 31: North America – Market size and forecast 2020-2025 ($ billion)
• 32: North America – Year-over-year growth 2020-2025 (%)
• 33: Europe – Market size and forecast 2020-2025 ($ billion)
• 34: Europe – Year-over-year growth 2020-2025 (%)
• 35: Asia – Market size and forecast 2020-2025 ($ billion)
• 36: Asia – Year-over-year growth 2020-2025 (%)
• 37: ROW – Market size and forecast 2020-2025 ($ billion)
• 38: ROW – Year-over-year growth 2020-2025 (%)
• 39: Key leading countries
• 40: Market opportunity by geography ($ billion)
• 41: Impact of drivers and challenges
• 42: Vendor landscape
• 43: Landscape disruption
• 44: Industry risks
• 45: Vendors covered
• 46: Market positioning of vendors
• 47: Abbott Laboratories – Overview
• 48: Abbott Laboratories – Business segments
• 49: Abbott Laboratories – Key offerings
• 50: Abbott Laboratories – Key customers
• 51: Abbott Laboratories – Segment focus
• 52: B. Braun Melsungen AG – Overview
• 53: B. Braun Melsungen AG – Business segments
• 54: B. Braun Melsungen AG – Key offerings
• 55: B. Braun Melsungen AG – Key customers
• 56: B. Braun Melsungen AG – Segment focus
• 57: Bionime Corp. – Overview
• 58: Bionime Corp. – Product and service
• 59: Bionime Corp. – Key offerings
• 60: Bionime Corp. – Key customers
• 61: Bionime Corp. – Segment focus
• 62: Dexcom Inc. – Overview
• 63: Dexcom Inc. – Business segments
• 64: Dexcom Inc. – Key offerings
• 65: Dexcom Inc. – Key customers
• 66: Dexcom Inc. – Segment focus
• 67: Eli Lilly and Co. – Overview
• 68: Eli Lilly and Co. – Business segments
• 69: Eli Lilly and Co. – Key offerings
• 70: Eli Lilly and Co. – Key customers
• 71: Eli Lilly and Co. – Segment focus
• 72: F. Hoffmann-La Roche Ltd. – Overview
• 73: F. Hoffmann-La Roche Ltd. – Business segments
• 74: F. Hoffmann-La Roche Ltd. – Key offerings
• 75: F. Hoffmann-La Roche Ltd. – Key customers
• 76: F. Hoffmann-La Roche Ltd. – Segment focus
• 77: LifeScan IP Holdings LLC – Overview
• 78: LifeScan IP Holdings LLC – Product and service
• 79: LifeScan IP Holdings LLC – Key offerings
• 80: LifeScan IP Holdings LLC – Key customers
• 81: LifeScan IP Holdings LLC – Segment focus
• 82: Medtronic Plc – Overview
• 83: Medtronic Plc – Business segments
• 84: Medtronic Plc – Key offerings
• 85: Medtronic Plc – Key customers
• 86: Medtronic Plc – Segment focus
• 87: Novo Nordisk AS – Overview
• 88: Novo Nordisk AS – Business segments
• 89: Novo Nordisk AS – Key offerings
• 90: Novo Nordisk AS – Key customers
• 91: Novo Nordisk AS – Segment focus
• 92: PHC Holdings Corp. – Overview
• 93: PHC Holdings Corp. – Business segments
• 94: PHC Holdings Corp. – Key offerings
• 95: PHC Holdings Corp. – Key customers
• 96: PHC Holdings Corp. – Segment focus
• 97: Currency conversion rates for US$
• 98: Research Methodology
• 99: Validation techniques employed for market sizing
• 100: Information sources
• 101: List of abbreviations



【掲載企業】

Abbott Laboratories, B. Braun Melsungen AG, Bionime Corp., Dexcom Inc., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., LifeScan IP Holdings LLC, Medtronic Plc, Novo Nordisk AS, PHC Holdings Corp.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[糖尿病管理デバイスの世界市場2021年-2025年]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆